Wednesday, May 11, 2016 5:41:18 PM
While extremely subtle It may again show how impressed the FDA is with MNTA's analytics as their thinking evolves in the evaluation and approval of generic biologics under the 351(k) pathway.
Although, not likely to affect other biosimilar players nearly as positively IMO since MNTA has been the only one that has articulated and pursued a "bio-same" with "fingerprint" similarity and fully interchangeable strategy in contrast to just a "bio-similar" generic strategy (similar to the traditional compounds business) pursued by almost all other players.
While still early to draw meaningful conclusions it would seem that though Novartis was first out of the gates with an approved biosimilar its uptake has been less than stellar - likely because its not rated as interchangeable....so the just generic biosimilar strategy may not prove to be the winning formula in approaching the complex biologics generics business.
VHAI - Vocodia Partners with Leading Political Super PACs to Revolutionize Fundraising Efforts • VHAI • Sep 19, 2024 11:48 AM
Dear Cashmere Group Holding Co. AKA Swifty Global Signs Binding Letter of Intent to be Acquired by Signing Day Sports • DRCR • Sep 19, 2024 10:26 AM
HealthLynked Launches Virtual Urgent Care Through Partnership with Lyric Health. • HLYK • Sep 19, 2024 8:00 AM
Element79 Gold Corp. Appoints Kevin Arias as Advisor to the Board of Directors, Strengthening Strategic Leadership • ELMGF • Sep 18, 2024 10:29 AM
Mawson Finland Limited Further Expands the Known Mineralized Zones at Rajapalot: Palokas step-out drills 7 metres @ 9.1 g/t gold & 706 ppm cobalt • MFL • Sep 17, 2024 9:02 AM
PickleJar Announces Integration With OptCulture to Deliver Holistic Fan Experiences at Venue Point of Sale • PKLE • Sep 17, 2024 8:00 AM